Skip to main content
. 2014 Apr 16;8(1):211–217. doi: 10.3892/ol.2014.2071

Figure 6.

Figure 6

Matrix metalloproteinase-2 (MMP-2) expression in melanoma cells with overexpression and knockdown of angiopoietin-like 4 (ANGPTL4) and/or aldolase A (ALDOA). (A) WM-115 cells: MMP-2 expression was determined in control cells (lane 1), cells stably transfected with empty pcDNA3 vector (lane 2), cells overexpressing ANGPTL4 (lane 3), cells stably expressing ALDOA-shRNA (lane 4), and cells overexpressing ANGPTL4 plus stably expressing ALDOA-shRNA (lane 5), by western blot analysis. WM-266-4 cells: MMP-2 expression was determined in control cells, cells stably transduced with scramble control shRNA (lane 7), cells stably expressing ANGPTL4-shRNA (lane 8), cells overexpressing ALDOA (lane 9), and cells stably expressing ANGPTL4-shRNA plus overexpressing ALDOA (lane 10), by western blot analysis. β-actin blotting was used as a loading control. (B) The density of the MMP-2 blot was normalized against that of β-actin to obtain a relative blot density, which was expressed as the fold-change to the relative MMP-2 blot density of WM-115 control cells (designated as 1). WM-115 cells: αP<0.05, compared with Control and Vector; βP<0.05, compared with ANGPTL4; γP<0.05, compared with ALDOA-shRNA. WM-266-4 cells: δP<0.05, compared with Control and Scramble; χP<0.05, compared with ANGPTL4-shRNA.